NasdaqGM - Nasdaq Real Time Price USD

Neuphoria Therapeutics Inc. (NEUP)

3.0200 -0.0300 (-0.98%)

As of 2:38:48 PM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development

GlobeNewswire 1mo ago

SCLP.L

NEUP
-0.98%
BLK
Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell

PREMIUM
MT Newswires 3mo ago

SCLP.L

NEUP
-0.98%
BLK
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

GlobeNewswire 4mo ago

SCLP.L

NEUP
-0.98%
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders

PR Newswire 10mo ago

NEUP
-0.98%
Scancell confirms advanced talks over reverse merger with Neuphoria

Proactive 4mo ago

SCLP.L

NEUP
-0.98%
SCNLF
Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial

Proactive 24d ago

SCLP.L

NEUP
-0.98%
BLK
Scancell sees high demand in retail share offer, seals £15.7m from UK investors

Proactive 3mo ago

SCLP.L

NEUP
-0.98%
SCNLF
SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612

Proactive 3mo ago

SCLP.L

NEUP
-0.98%
SCP.F
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

GlobeNewswire 3mo ago

NEUP
-0.98%
SCLP
MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership

Stocktwits 3mo ago

MRK

NEUP
-0.98%
Leading Advisory Firms Recommend Voting FOR Lynx1's Independent Nominees

PR Newswire 10mo ago

NEUP
-0.98%
Here's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Situation

Simply Wall St. 8mo ago

NEUP
-0.98%

Performance Overview

Return	NEUP	S&P 500 (^GSPC)
YTD	-21.39%	+11.09%
1-Year	-32.97%	+11.18%
3-Year	-89.32%	+76.13%

U.S. markets close in 1h 10m

Neuphoria Therapeutics Inc. (NEUP)

Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development

Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders

Scancell confirms advanced talks over reverse merger with Neuphoria

Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial

Scancell sees high demand in retail share offer, seals £15.7m from UK investors

SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612

Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership

Leading Advisory Firms Recommend Voting FOR Lynx1's Independent Nominees

Here's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Situation